{"id":"https://openalex.org/W3209817601","doi":"https://doi.org/10.1136/ijgc-2021-igcs.199","title":"EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis","display_name":"EPV129/#529 Long-term clinical and economic value of pembrolizumab + lenvatinib compared with chemotherapy in previously treated advanced endometrial cancer patients in Sweden: a cost-effectiveness analysis","publication_year":2021,"publication_date":"2021-11-01","ids":{"openalex":"https://openalex.org/W3209817601","doi":"https://doi.org/10.1136/ijgc-2021-igcs.199","mag":"3209817601"},"language":"en","primary_location":{"id":"doi:10.1136/ijgc-2021-igcs.199","doi":"https://doi.org/10.1136/ijgc-2021-igcs.199","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ijgc-2021-igcs.199","pdf_url":"https://ijgc.bmj.com/content/ijgc/31/Suppl_4/A81.2.full.pdf","source":{"id":"https://openalex.org/S41026820","display_name":"International Journal of Gynecological Cancer","issn_l":"1048-891X","issn":["1048-891X","1525-1438"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Gynecological Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ijgc.bmj.com/content/ijgc/31/Suppl_4/A81.2.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5074126560","display_name":"Navneet Upadhyay","orcid":"https://orcid.org/0000-0003-3776-9596","observed_orcids":["https://orcid.org/0000-0003-3776-9596"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Upadhyay","raw_affiliation_strings":["Merck and Co., Inc., Center of Observational and Real World Evidence, Kenilworth, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck and Co., Inc., Center of Observational and Real World Evidence, Kenilworth, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079073917","display_name":"Lewis Ralph","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159506","display_name":"BresMed","ror":"https://ror.org/05fd45014","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210159506"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"L. Ralph","raw_affiliation_strings":["BresMed Health Solutions Ltd, Health Economics, Sheffield, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BresMed Health Solutions Ltd, Health Economics, Sheffield, UK","institution_ids":["https://openalex.org/I4210159506"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087411596","display_name":"Christina Ljungcrantz","orcid":"https://orcid.org/0000-0003-2002-5507","observed_orcids":["https://orcid.org/0000-0003-2002-5507"]},"institutions":[{"id":"https://openalex.org/I4210105323","display_name":"MSD (Sweden)","ror":"https://ror.org/01eqvd516","country_code":"SE","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210105323"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"C. Ljungcrantz","raw_affiliation_strings":["MSD Sweden, Market Access, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MSD Sweden, Market Access, Stockholm, Sweden","institution_ids":["https://openalex.org/I4210105323"]}]},{"author_position":"middle","author":{"id":null,"display_name":"A. Merchant","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159506","display_name":"BresMed","ror":"https://ror.org/05fd45014","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210159506"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"A. Merchant","raw_affiliation_strings":["BresMed Health Solutions Ltd, Health Economics, Sheffield, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BresMed Health Solutions Ltd, Health Economics, Sheffield, UK","institution_ids":["https://openalex.org/I4210159506"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051966517","display_name":"B Haycroft","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210159506","display_name":"BresMed","ror":"https://ror.org/05fd45014","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210159506"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"B. Haycroft","raw_affiliation_strings":["BresMed Health Solutions Ltd, Health Economics, Sheffield, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BresMed Health Solutions Ltd, Health Economics, Sheffield, UK","institution_ids":["https://openalex.org/I4210159506"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028667662","display_name":"Anna Fornwall","orcid":"https://orcid.org/0009-0000-7364-6820","observed_orcids":["https://orcid.org/0009-0000-7364-6820"]},"institutions":[{"id":"https://openalex.org/I4210148008","display_name":"Quantify Research (Sweden)","ror":"https://ror.org/05nqb8479","country_code":"SE","type":"company","lineage":["https://openalex.org/I4210148008"]}],"countries":["SE"],"is_corresponding":false,"raw_author_name":"A. Fornwall","raw_affiliation_strings":["Quantify Research, Health Economics, Stockholm, Sweden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quantify Research, Health Economics, Stockholm, Sweden","institution_ids":["https://openalex.org/I4210148008"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062529556","display_name":"Vimalanand S. Prabhu","orcid":"https://orcid.org/0000-0003-1358-8846","observed_orcids":["https://orcid.org/0000-0003-1358-8846"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V. Prabhu","raw_affiliation_strings":["Merck and Co., Inc., Center of Observational and Real World Evidence, Kenilworth, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck and Co., Inc., Center of Observational and Real World Evidence, Kenilworth, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050009430","display_name":"Robert J. Orlowski","orcid":"https://orcid.org/0000-0002-8037-9932","observed_orcids":["https://orcid.org/0000-0002-8037-9932"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Orlowski","raw_affiliation_strings":["Merck and Co., Inc., Late Stage Clinical Development, Kenilworth, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck and Co., Inc., Late Stage Clinical Development, Kenilworth, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009462256","display_name":"Linda Duska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I51556381","display_name":"University of Virginia","ror":"https://ror.org/0153tk833","country_code":"US","type":"education","lineage":["https://openalex.org/I51556381"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Duska","raw_affiliation_strings":["University of Virginia, Department of Obstetrics and Gynecology, Charlottesville, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Virginia, Department of Obstetrics and Gynecology, Charlottesville, USA","institution_ids":["https://openalex.org/I51556381"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3800,"currency":"USD","value_usd":3800},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":null,"first_page":"A81","last_page":"A81"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.022600000724196434,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-endometrial-cancer","display_name":"advanced endometrial cancer","score":0.9010000228881836},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/lenvatinib","display_name":"lenvatinib","score":1.0},{"id":"https://openalex.org/keywords/chemotherapy","display_name":"chemotherapy","score":0.6990000009536743},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8690000176429749},{"id":"https://openalex.org/keywords/previously-treated-patients","display_name":"previously treated patients","score":0.722000002861023},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.875},{"id":"https://openalex.org/keywords/life-years","display_name":"life-years","score":0.6230000257492065},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.8650000095367432},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.49000000953674316},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.6790000200271606},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9580000042915344}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7737902998924255},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.6479761600494385},{"id":"https://openalex.org/C2776264508","wikidata":"https://www.wikidata.org/wiki/Q6523413","display_name":"Lenvatinib","level":4,"score":0.6025760173797607},{"id":"https://openalex.org/C2777088508","wikidata":"https://www.wikidata.org/wiki/Q944777","display_name":"Endometrial cancer","level":3,"score":0.5603191256523132},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5483255982398987},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5442498326301575},{"id":"https://openalex.org/C2776738588","wikidata":"https://www.wikidata.org/wiki/Q1567856","display_name":"Pharmacoeconomics","level":2,"score":0.531252384185791},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.5066366791725159},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5025553703308105},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.48861271142959595},{"id":"https://openalex.org/C2776125615","wikidata":"https://www.wikidata.org/wiki/Q18391886","display_name":"Economic evaluation","level":2,"score":0.4665301442146301},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.43553411960601807},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.42779189348220825},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.42302292585372925},{"id":"https://openalex.org/C515549039","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost-effectiveness analysis","level":3,"score":0.4106011986732483},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3261268138885498},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.28181833028793335},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.1147950291633606},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/ijgc-2021-igcs.199","doi":"https://doi.org/10.1136/ijgc-2021-igcs.199","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ijgc-2021-igcs.199","pdf_url":"https://ijgc.bmj.com/content/ijgc/31/Suppl_4/A81.2.full.pdf","source":{"id":"https://openalex.org/S41026820","display_name":"International Journal of Gynecological Cancer","issn_l":"1048-891X","issn":["1048-891X","1525-1438"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Gynecological Cancer","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1136/ijgc-2021-igcs.199","doi":"https://doi.org/10.1136/ijgc-2021-igcs.199","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ijgc-2021-igcs.199","pdf_url":"https://ijgc.bmj.com/content/ijgc/31/Suppl_4/A81.2.full.pdf","source":{"id":"https://openalex.org/S41026820","display_name":"International Journal of Gynecological Cancer","issn_l":"1048-891X","issn":["1048-891X","1525-1438"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Gynecological Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3209817601.pdf","grobid_xml":"https://content.openalex.org/works/W3209817601.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W6939641217","https://openalex.org/W4229447448","https://openalex.org/W4394763585","https://openalex.org/W4283743198","https://openalex.org/W4298145339","https://openalex.org/W7124167335","https://openalex.org/W4386948924","https://openalex.org/W3186092871","https://openalex.org/W4311331505","https://openalex.org/W4391096098"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2021-11-08T00:00:00"}